Company
Headquarters: Xiamen, China
Employees: 840
CN¥8.21 Billion
CNY as of Jan. 1, 2026
US$1.17 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.13 B |
| EBITDA | CN¥377.2 M |
| Gross Profit TTM | CN¥934.0 M |
| Profit Margin | 25.75% |
| Operating Margin | 21.31% |
| Quarterly Revenue Growth | -6.10% |
Amoy Diagnostics Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300685